N-Acylethanolamines: Emerging Lipid Messengers for Metabolic and Brain Health

From appetite control to neuroprotection, N-acylethanolamines (NAEs) are emerging as powerful lipid messengers that connect metabolism, inflammation, and brain health through intricate biochemical signaling pathways.

What are NAEs?

N-acylethanolamines (NAEs) are lipid-based endogenous signaling molecules formed by combining long-chain fatty acids with ethanolamine. They encompass both endocannabinoids and structurally related lipid mediators that don’t directly activate cannabinoid receptors. The biosynthesis of NAEs begins with N-acyltransferases, which transfer an acyl chain from phospholipids to phosphatidylethanolamine (PE), creating N-acyl-phosphatidylethanolamine (NAPE), the direct precursor to NAEs.

This initial step involves enzymes like Ca²⁺-dependent cytosolic phospholipase A2ε (cPLA2ε) and Ca²⁺-independent phospholipase A and acyltransferase (PLAAT). NAPE is then converted to NAEs primarily by NAPE-hydrolyzing phospholipase D (NAPE-PLD), though alternative multi-step pathways involving α/β-hydrolase domain-containing protein 4 (ABHD4), lysophospholipase reactions, and glycerophosphodiesterases (GDE1 and GDE4) also exist. [1]

NAE activity is determined by the type of fatty acid in its structure. Anandamide (AEA) activates cannabinoid receptors, classifying it as an endocannabinoid. Other NAEs, like N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA), primarily act through non-cannabinoid pathways, including peroxisome proliferator-activated receptor-α (PPARα) signaling. [2] PEA, OEA, and stearolyethanolamide (SEA) are abundant NAEs derived from palmitic, oleic, and stearic acids, respectively, and generally exert biological effects through PPARα or other non-cannabinoid signaling mechanisms.

NAEs in Metabolic Health

NAEs play a significant role in regulating inflammation, a common feature of metabolic disorders. PEA, originally isolated from soybeans, eggs, and peanuts, exhibits anti-inflammatory, analgesic, anti-epileptic, and neuroprotective properties, largely attributed to its interaction with PPARα signaling pathways. [2] It’s been studied for treating chronic inflammatory conditions like eczema, pain, and neurodegeneration and is available as a natural food supplement in the United States and Europe. [2]

OEA, produced in the small intestine after dietary fat intake, also binds to PPARα, leading to anorexic activity, suggesting a link between OEA dysfunction and weight gain. [2] It can also engage receptors like GPR119 and influence satiety signaling pathways involved in energy balance.

NAEs and Cognition

Docosahexaenoylethanolamide (synaptamide), derived from docosahexaenoic acid (an omega-3 fatty acid), promotes the formation of latest neurons and synapses via G-protein coupled receptor 110 (GPR110). [2] This signaling pathway is linked to increased neurogenesis, neurite outgrowth, and synapse formation.

NAEs also regulate neuroinflammation, requiring a balance between protective activity and preventing negative consequences. Higher intracranial levels of NAEs like AEA, OEA, PEA, and DHEA can influence immune responses by reducing glial activation and pro-inflammatory cytokine release, potentially involving cannabinoid receptors, transient receptor potential channels like TRPV1, and PPARα. [2] Dysregulated brain NAE levels have been reported in neurological disorders, with elevated AEA levels observed in cerebrospinal fluid (CSF) samples from patients with multiple sclerosis and Parkinson’s disease. [2]

Therapeutic and Lifestyle Implications

NAEs are found in both plant and animal sources. OEA is abundant in wheat, flour, cocoa, and coffee, even as PEA is found in corn, tomatoes, peanuts, soybeans, and cotton seeds. Animal products like eggs, chicken, and beef contain AEA, as well as DHEA and eicosapentaenoylethanolamine (EPEA).

Within cells, NAE concentrations are controlled by biosynthetic pathways and enzymatic degradation. Caloric intake and dietary fat composition modulate enzymes involved in NAE biosynthesis, including cytosolic phospholipase A2 ε (cPLA2ε) and phospholipase A and acyltransferase (PLAAT). NAEs can also undergo oxidative metabolism by enzymes like cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 enzymes.

Pharmacological inhibition of fatty acid amide hydrolase (FAAH), the primary enzyme that breaks down AEA in the brain, increases endogenous NAE levels. While FAAH inhibitors are under investigation, widespread approval is limited due to safety concerns observed in earlier clinical trials.

Challenges and Future Directions

Most studies on NAE activity have been conducted in animal models, limiting the generalizability of findings to humans. Further research with human cohorts is needed to clarify tissue-specific regulation, compensatory pathways, and the long-term safety and efficacy of targeting NAE metabolism. The presence of multiple biosynthetic and metabolic pathways for NAEs complicates interpretation and highlights the need for more selective pharmacological tools.

Conclusions

NAEs are versatile endogenous lipid mediators that integrate nutrient sensing, inflammation, appetite regulation, and energy metabolism. While significant translational challenges remain, NAEs represent potential molecular targets for therapeutic, nutritional, and lifestyle strategies to improve metabolic health and promote healthy aging. Ongoing research continues to reveal new opportunities for targeting lipid signaling networks in metabolic, inflammatory, and neurological disorders.